PET in breast cancer*
References (58)
- et al.
Characterization of the uptake of 16α[18F] fluoro-17β-estradiol in DMBA-induced mammary tumors
Int J Rad Appl Instrum [B]
(1987) - et al.
NCA 16α-[18F]fluoroestradiol-17β: the effect of reaction vessel on fluorine-18 resolubilization, product yield and effective specific activity
Int J Radiat Appl Instrum [A]
(1986) - et al.
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy
Lancet
(1981) - et al.
Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16α-ethyl-19-norprogesterone) in humans: a clue for future investigations
Nucl Med Biol
(1994) - et al.
Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues
Life Sci
(1994) - et al.
Cancer statistics 1998
CA Cancer J Clin
(1992) - et al.
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
Eur J Nucl Med
(1996) The metabolism of tumors
- et al.
Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
J Natl Cancer Inst
(1978) - et al.
Molecular events leading to enhanced glucose transport in Rous sarcoma virus-transformed cells
Federation Proc
(1984)
Over expression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study
Cancer
Local threshold for segmented attenuation correction of PET imaging of the thorax
IEEE Trans Nucl Sci
Lung tumor imaging by positron emission tomography using C-11 L-methionine
J Nucl Med
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction
Radiology
Breast imaging with fluorine-18-FDG PET: quantitative image analysis
J Nucl Med
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
J Clin Oncol
Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma
Radiology
Graphical evaluation of blood-to-brain transfer constant from multiple-time uptake data. Generalization
J Cereb Blood Flow Metab
Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation
J Clin Oncol
Efficacy of breast cancer screening by age. New results from Swedish two-country trial
Cancer
The application of positron emission tomography with fluorodeoxyglucose to the evaluation of breast disease
Ann Surg
Primary and metastatic breast carcinoma: initial clinical evaluation with PEt with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
Radiology
Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
Cancer
Quantitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability
Eur J Nucl Med
Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
Radiology
Cancer detection with whole-body PET using [18F]fluoro-2-deoxy-D-glucose
J Comput Assist Tomogr
Intratumoral distribution of fluorine-18-deoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiographic comparison with FDG
J Nucl Med
Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-deoxyglucose-PET
J Nucl Med
Cancer of the breast
Cited by (102)
16α-[<sup>18</sup>F]-fluoro-17ß-oestradiol ([<sup>18</sup>F]FES): A biomarker for imaging oestrogen receptor expression with positron emission tomography (PET)
2015, Medecine NucleaireCitation Excerpt :In contrast to uterine tissues, human breast cancer [18F]FES uptake does not seem to be affected by exogenous oestradiol administration or other hormonal status variables [40,41]. In human breast cancers, [18F]FES has been used for predicting the response to treatment [42] and for demonstrating the anti-oestrogenic effect of tamoxifen [26]. A metabolic flare resulting in a transient increase in tumour [18F]FDG uptake was sometimes reported in the early days after the onset of endocrine therapy and was usually followed by clinical remission [43].
Dedicated PET device for breast PET and MRI/PET correlations
2012, European Journal of RadiologyPET and PET-CT Imaging in Treatment Monitoring of Breast Cancer
2009, PET ClinicsCitation Excerpt :This technique was followed by imaging using monoclonal antibodies against carcinoembryonic antigens and other antigens expressed in breast cancer and imaging with 99mTc-tetrofosmin or 99mTc-sestamibi for primary and recurrent disease.17,18 Since the introduction of positron emission tomography (PET) in clinical oncology, 18F-fluorodeoxyglucose (18F-FDG) PET has been shown to be an effective and accurate imaging modality for staging and restaging of recurrent and metastatic disease and for treatment monitoring.19–22 Sequential 18F-FDG PET imaging has been widely studied as a method for assessing tumor response to neoadjuvant chemotherapy.
Positron Emission Tomography/Computed Tomography: The Current Technology and Applications
2009, Radiologic Clinics of North AmericaCitation Excerpt :FDG PET has a limited role in the diagnosis of breast cancer,34 but it is important in detecting locoregional (including nodal) and distant disease, in helping to plan surgical and medical treatment, in monitoring response to treatment, and in finding recurrence.35–41 PET also has the potential to evaluate novel treatment agents rapidly by detecting their effects on specific receptors37,42 and has been shown to improve prediction of the clinical outcome in patients who have previously treated breast cancer.43,44 For thyroid cancer, FDG PET is approved for restaging patients who have thyroglobulin-positive, iodine-negative disease.
Synthesis of new carbon-11 labeled naphthalene-sulfonamides for PET imaging of human CCR8
2008, Applied Radiation and Isotopes
- *
Supported in part by National Cancer Institute grant no. CA48286.